ASTRAZENECA
Updates & Highlights
Is It Too Late To Reassess AstraZeneca (LSE:AZN) After Its Strong Multi‑Year Run?
Is It Too Late To Reassess AstraZeneca (LSE:AZN) After Its Strong Multi‑Year Run?
Yahoo Finance · about 4 hours ago
AstraZeneca Advances Early Combo Drug Study With Fresh Clinical Update
AstraZeneca Advances Early Combo Drug Study With Fresh Clinical Update
TipRanks · about 13 hours ago
AstraZeneca advances oral GLP-1 elecoglipron into Phase III
AstraZeneca advances oral GLP-1 elecoglipron into Phase III
The Pharma Letter · about 15 hours ago
Recent Openings
View all 9 jobsPrincipal AI Engineer - Evinova
Barcelona, CT, ES
Senior AI Engineer
Cambridge, ENG, GB
Associate Principal AI & ML Engineer – Evinova
London, ENG, GB
Associate Principal AI Research Scientist (Fundamental AI Research for Digital Biology)
Boston, MA, US
All Jobs
Principal AI Engineer - Evinova
Barcelona, CT, ES
Senior AI Engineer
Cambridge, ENG, GB
Associate Principal AI & ML Engineer – Evinova
London, ENG, GB
Associate Principal AI Research Scientist (Fundamental AI Research for Digital Biology)
Boston, MA, US
Principal AI& ML Engineer – Evinova
London, ENG, GB
Associate Principal AI& ML Engineer – Evinova
London, ENG, GB
Associate Principal AI Research Scientist (Fundamental AI Research for Digital Biology)
Wilmington, DE, US
Data & AI Engineer Intern
Barcelona, CT, ES
Principal AI Engineer - Evinova
Barcelona, CT, ES
Culture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
401(k) Match
Retirement savings
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at AstraZeneca?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company →News & Press
20 recentIs It Too Late To Reassess AstraZeneca (LSE:AZN) After Its Strong Multi‑Year Run?
Is It Too Late To Reassess AstraZeneca (LSE:AZN) After Its Strong Multi‑Year Run?
Yahoo Finance · about 4 hours ago
AstraZeneca Advances Early Combo Drug Study With Fresh Clinical Update
AstraZeneca Advances Early Combo Drug Study With Fresh Clinical Update
TipRanks · about 13 hours ago
Functional genomics & AI advances AstraZeneca drug discovery- SelectScience interview
Functional genomics & AI advances AstraZeneca drug discovery- SelectScience interview
Select Science · about 14 hours ago
AstraZeneca advances oral GLP-1 elecoglipron into Phase III
AstraZeneca advances oral GLP-1 elecoglipron into Phase III
The Pharma Letter · about 15 hours ago
Lung Cancer Research Foundation and AstraZeneca Announce Open Call for Research Proposals with Focus on Small Cell Lung Cancer
Lung Cancer Research Foundation and AstraZeneca Announce Open Call for Research Proposals with Focus on Small Cell Lung Cancer
PR Newswire · about 16 hours ago
ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data
ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data
BioSpace · about 17 hours ago
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA
Clinical Trials Arena · about 18 hours ago
AstraZeneca reprimanded over LinkedIn likes once again
AstraZeneca reprimanded over LinkedIn likes once again
Fierce Pharma · about 19 hours ago
Encouraging trial results for AstraZeneca's new weight-loss pill
Encouraging trial results for AstraZeneca's new weight-loss pill
Medical Xpress · about 20 hours ago
AstraZeneca unveils data behind Phase III-bound oral GLP-1
AstraZeneca unveils data behind Phase III-bound oral GLP-1
FirstWord Pharma · 1 day ago
LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
Stocktwits · 1 day ago
AstraZeneca CEO Pascal Soriot delivers remarks as firm celebrates transfer to NYSE
AstraZeneca CEO Pascal Soriot delivers remarks as firm celebrates transfer to NYSE
qz.com · 1 day ago
AstraZeneca advancing elecoglipron into Phase 3 program in obesity, T2D
AstraZeneca advancing elecoglipron into Phase 3 program in obesity, T2D
TipRanks · 1 day ago
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
Reuters · 1 day ago
AstraZeneca CFO Dr. Aradhana Sarin breaks down revenue growth goals
AstraZeneca CFO Dr. Aradhana Sarin breaks down revenue growth goals
qz.com · 1 day ago
Elecoglipron cut nearly 12% of body weight in study, AstraZeneca says
Elecoglipron cut nearly 12% of body weight in study, AstraZeneca says
NewsNation · 1 day ago
Hong Kong's urban development near China border draws AstraZeneca, others
Hong Kong's urban development near China border draws AstraZeneca, others
Nikkei Asia · 1 day ago
AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
statnews.com · 1 day ago
AstraZeneca advances weight-loss pill to take aim at obesity leaders
AstraZeneca advances weight-loss pill to take aim at obesity leaders
Financial Times · 1 day ago
Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio
Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio
AstraZeneca · 1 day ago